The European Commission approves Bio-Thera’s BAT2206 (USYMRO®, a biosimilar ustekinumab), to be commercialized by Richter in Europe
27/08/2025
Business related Regulatory Biotechnology API - USTEKINUMAB PARTNER - BIO-THERA